

REMARKS

The claims have been amended to reduce improper multiple dependencies, without prejudice. Claims 11-20 find support throughout the specification. No new matter has been added. A marked-up copy of the amended claims is attached.

The specification has been amended to include amended pages 4-8 and the attached Sequence Listing. Amended pages 4-8 attached contain the sequence identifiers, consistent with the attached Sequence Listing. A marked up copy of pages 4-8 is also attached indicating where additions have been made. No new matter has been added.


The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

BJS:Imy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

MARKED UP COPY OF AMENDED CLAIMS

1. (Amended) A method of preparing a medicament for treating oedema comprising admixing [Use of a peptide comprising] a chain of 7 to 17 contiguous amino acids derived from the region of human TNF- α from Ser¹⁰⁰ to Glu¹¹⁶ or from the region of mouse TNF- α from Ser⁹⁹ to Glu¹¹⁵ [for the manufacture of a medicament for treating oedema] with a pharmaceutically acceptable carrier.

2. (Amended) [Use of a peptide] A method according to claim 1, wherein said peptide comprises a chain of 11 to 16 contiguous amino acids.

3. (Amended) [Use of a peptide] A method according to claim 1, wherein said peptide comprises a chain of 13 to 15 contiguous amino acids.

4. (Amended) [Use of a peptide] A method according to claim 1, wherein said peptide comprises a chain of 14 contiguous amino acids.

5. (Amended) [Use of a peptide] A method according to claim 4, wherein said chain of 14 contiguous amino acids are chosen from the group consisting of the contiguous amino acid sequences

QRETPEGAEAKPWY and PKDTPEGAEELKPWY.

6. (Amended) [Use of a peptide] A method according to [any of claims 1 to 5]

claim 1, wherein said peptide is circularized.

7. (Amended) [Use of a peptide] A method according to claim 6, wherein said peptide is circularized by replacing the NH₂- and COOH-terminal amino acids by cysteine so that a disulfide bridge is formed between the latter cysteines.

8. (Amended) A method [Use of a peptide] according to claim 7, wherein said circularized peptides are chosen from the group consisting of the circularized peptides CGQRETPEGAEAKPWYC and CGPKDTPEGAEELKPWYC.

9. (Amended) A method [Use of a peptide] according to [any of claims 1 to 8] claim 1, wherein said oedema is pulmonary oedema.

10. (Amended) A pharmaceutical composition for treating oedema comprising [a peptide according to any of claims 1 to 9] a chain of 7 to 17 contiguous amino acids derived from the region of human TNF- α from Ser¹⁰⁰ to Glu¹¹⁶ or from the region of mouse TNF- α from Ser⁹⁹ to Glu¹¹⁵ and a pharmaceutically acceptable carrier.